NEU-411

DRUG3 trials

Sponsors

Neuron23 Inc.

Conditions

Early Parkinson DiseaseEarly Parkinson Disease (Early PD)HealthyIdiopathicIdiopathic Parkinson DiseaseParkinsonParkinson DiseaseParkinson Disease, Idiopathic

Phase 1

A Study to Assess NEU-411 in Healthy Participants

CompletedNCT05755191

Neuron23 Inc.Healthy

Start: 2023-05-13End: 2024-06-03Updated: 2025-02-24

Phase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

RecruitingNCT06680830

Neuron23 Inc.Early Parkinson Disease (Early PD), Idiopathic Parkinson Disease, Parkinson +2

Start: 2025-01-17End: 2028-06-01Target: 150Updated: 2026-08-28

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)

Not yet recruitingCTIS2024-515448-22-00

Neuron23 Inc.Early Parkinson Disease, Idiopathic, Idiopathic Parkinson Disease +3

Target: 60Updated: 2026-01-26